155 related articles for article (PubMed ID: 16259869)
1. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
[TBL] [Abstract][Full Text] [Related]
2. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial.
Wallner K; Merrick G; True L; Cavanagh W; Simpson C; Butler W
Cancer J; 2002; 8(1):67-73. PubMed ID: 11895205
[TBL] [Abstract][Full Text] [Related]
3. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
4. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
[TBL] [Abstract][Full Text] [Related]
5. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
6. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.
Sherertz T; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W; True L
Brachytherapy; 2004; 3(3):130-5. PubMed ID: 15533804
[TBL] [Abstract][Full Text] [Related]
7. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.
Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1297-303. PubMed ID: 14630265
[TBL] [Abstract][Full Text] [Related]
8. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
9. Clinical correlates of high intraprostatic brachytherapy dose volumes.
Jones S; Wallner K; Merrick G; Corriveau J; Sutlief S; True L; Butler W
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):328-33. PubMed ID: 12023136
[TBL] [Abstract][Full Text] [Related]
10. Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications.
Peschel RE; Colberg JW; Chen Z; Nath R; Wilson LD
Cancer J; 2004; 10(3):170-4. PubMed ID: 15285926
[TBL] [Abstract][Full Text] [Related]
11. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
12. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract][Full Text] [Related]
13. Epididymitis after prostate brachytherapy.
Hoffelt SC; Wallner K; Merrick G
Urology; 2004 Feb; 63(2):293-6. PubMed ID: 14972474
[TBL] [Abstract][Full Text] [Related]
14. Argon plasma coagulation for rectal bleeding after prostate brachytherapy.
Smith S; Wallner K; Dominitz JA; Han B; True L; Sutlief S; Billingsley K
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):636-42. PubMed ID: 11597803
[TBL] [Abstract][Full Text] [Related]
15. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.
Snyder KM; Stock RG; Hong SM; Lo YC; Stone NN
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):335-41. PubMed ID: 11380219
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
17. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
[TBL] [Abstract][Full Text] [Related]
18. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
19. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
20. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
